Upgrade to SI Premium - Free Trial

BioXcel Therapeutics (BTAI)

1.11 +0.02 (1.83%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26)

Latest Headlines

BioXcel presents at-home agitation trial data at medical meeting May 28, 2026 7:00 AM - StreetInsider BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting May 28, 2026 7:00 AM - Globe NewsWire Form 4 BioXcel Therapeutics, For: May 04 Filed by: Yocca Frank May 22, 2026 7:03 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 04 Filed by: Rodriguez Javier May 22, 2026 7:02 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 04 Filed by: Steinhart Richard I May 22, 2026 7:02 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 04 Filed by: Mehta Vimal May 22, 2026 7:00 PM - SEC Filing Form 144 BioXcel Therapeutics, Filed by: Mehta Vimal May 20, 2026 4:29 PM - SEC Filing Form 144 BioXcel Therapeutics, Filed by: Rodriguez Javier May 20, 2026 4:28 PM - SEC Filing Form 144 BioXcel Therapeutics, Filed by: Yocca Frank May 20, 2026 4:27 PM - SEC Filing Form 144 BioXcel Therapeutics, Filed by: Steinhart Richard I May 20, 2026 4:25 PM - SEC Filing Form SCHEDULE 13G BioXcel Therapeutics, Filed by: ARMISTICE CAPITAL, LLC May 15, 2026 11:10 AM - SEC Filing Form 8-K BioXcel Therapeutics, For: May 15 May 15, 2026 7:07 AM - SEC Filing Form 10-Q BioXcel Therapeutics, For: Mar 31 May 15, 2026 7:06 AM - SEC Filing BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results May 15, 2026 7:00 AM - Globe NewsWire Form 4 BioXcel Therapeutics, For: May 01 Filed by: Mehta Vimal May 7, 2026 7:02 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 01 Filed by: Steinhart Richard I May 7, 2026 7:01 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 01 Filed by: Yocca Frank May 7, 2026 7:01 PM - SEC Filing Form 4 BioXcel Therapeutics, For: May 01 Filed by: Rodriguez Javier May 7, 2026 7:00 PM - SEC Filing Form 8-K BioXcel Therapeutics, For: Apr 15 April 21, 2026 9:08 AM - SEC Filing Form 8-K BioXcel Therapeutics, For: Apr 15 April 17, 2026 5:01 PM - SEC Filing BioXcel to host virtual event on IGALMI commercial launch strategy April 17, 2026 7:01 AM - StreetInsider BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting April 17, 2026 7:01 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI) April 10, 2026 6:49 AM - StreetInsider BioXcel starts U.S. Department of War-funded trial for stress treatment April 8, 2026 7:02 AM - StreetInsider BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions April 8, 2026 7:00 AM - Globe NewsWire BioXcel Therapeutics (BTAI) PT Lowered to $5 at H.C. Wainwright April 2, 2026 6:42 AM - StreetInsider FDA accepts BioXcel Therapeutics application for at-home IGALMI use April 1, 2026 7:03 AM - StreetInsider FDA accepts BioXcel's application for IGALMI at-home use April 1, 2026 7:01 AM - StreetInsider BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting April 1, 2026 7:00 AM - Globe NewsWire BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting April 1, 2026 7:00 AM - StreetInsider Form 8-K BioXcel Therapeutics, For: Apr 01 April 1, 2026 6:58 AM - SEC Filing Form SCHEDULE 13G/A BioXcel Therapeutics, Filed by: Qatar Investment Authority March 30, 2026 12:11 PM - SEC Filing Form S-8 BioXcel Therapeutics, March 27, 2026 5:10 PM - SEC Filing Form 10-K BioXcel Therapeutics, For: Dec 31 March 27, 2026 5:02 PM - SEC Filing BioXcel Therapeutics (BTAI) Misses Q4 EPS by 58c March 27, 2026 8:16 AM - StreetInsider Form 8-K BioXcel Therapeutics, For: Mar 27 March 27, 2026 7:21 AM - SEC Filing BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting March 27, 2026 7:00 AM - StreetInsider Rodman & Renshaw Starts BioXcel Therapeutics (BTAI) at Buy, PT $17 March 17, 2026 7:57 AM - StreetInsider Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Mehta Vimal March 16, 2026 8:06 PM - SEC Filing Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Steinhart Richard I March 16, 2026 8:05 PM - SEC Filing Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Rodriguez Javier March 16, 2026 8:03 PM - SEC Filing Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Yocca Frank March 16, 2026 8:01 PM - SEC Filing Full Article List